Related Experiment Video

Updated: May 21, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Polo-like kinases inhibitors

L Garuti1, M Roberti, G Bottegoni

  • 1Department of Pharmaceutical Science, University of Bologna, via Belmeloro 6, I-40126 Bologna, Italy. laura.garuti@unibo.it

Current Medicinal Chemistry
|June 20, 2012
PubMed

Insights

Polo-like kinase 1 (PLK1) inhibitors show promise for cancer therapy by targeting unique features of the PLK1 active site or its polo-box domain (PBD). Research explores chemical structures, SAR, and biological activities for selective and potent drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Polo-like kinases (PLKs), particularly PLK1, are crucial for mitosis and frequently overexpressed in cancers, making them key therapeutic targets.
  • PLK1 inhibitors, mostly ATP-competitive, demonstrate selectivity through interactions with unique PLK1 active site features, including specific amino acid residues and pocket formations.
  • Alternative strategies involve targeting regions outside the ATP pocket or the unique polo-box domain (PBD) of PLK1 to enhance specificity and overcome drug resistance.

Purpose of the Study:

  • To review existing Polo-like kinase (PLK) inhibitors, focusing on their chemical structures, structure-activity relationships (SAR), and biological activities.
  • To highlight the potential of PLK inhibitors as selective and potent anticancer agents.
  • To explore combination therapies involving PLK inhibitors and other anticancer drugs for improved cancer treatment outcomes.

Main Methods:

  • Literature review of PLK inhibitors, analyzing their chemical structures and SAR.
  • Examination of biological activities and selectivity profiles of various PLK inhibitors.
  • Discussion of targeting strategies, including ATP-competitive inhibition, allosteric inhibition, and PBD inhibition.

Main Results:

  • Several classes of PLK inhibitors, including heterocyclic compounds, have been developed, demonstrating varying degrees of selectivity based on interactions with specific PLK1 binding site features.
  • Inhibitors targeting the PBD offer a unique approach for achieving specificity and overcoming resistance mechanisms.
  • Structure-activity relationship studies provide insights into optimizing inhibitor design for enhanced potency and selectivity.

Conclusions:

  • PLK inhibitors, especially those targeting unique PLK1 features or the PBD, hold significant therapeutic potential in oncology.
  • The development of selective PLK inhibitors is crucial for maximizing efficacy and minimizing off-target effects.
  • Combination therapies involving PLK inhibitors may offer novel and more effective strategies for cancer treatment.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: